Brief: Nabriva Therapeutics Provides Corporate Update

Nabriva Therapeutics

06/01/2023 12:11

Jan 6 (Reuters) - Nabriva Therapeutics PLC  NBRV.O :
    * NABRIVA THERAPEUTICS PROVIDES CORPORATE UPDATE
    * NABRIVA THERAPEUTICS PLC - COMPANY TO FOCUS ON PRESERVING
CASH
TO FUND ORDERLY WIND DOWN OF OPERATIONS
    * NABRIVA THERAPEUTICS PLC - COMPANY TO CONTINUE WORK WITH
TORREYA
CAPITAL ON ASSET MONETIZATION
    * NABRIVA THERAPEUTICS PLC - COMPANY TO FOCUS ON PRESERVING
CASH
TO FUND ORDERLY WIND DOWN OF OPERATIONS
    * NABRIVA THERAPEUTICS PLC - PLANS TO TERMINATE ALL
EMPLOYEES,
INCLUDING OFFICERS OF COMPANY, NOT DEEMED NECESSARY TO EXECUTE
AN ORDERLY WIND-DOWN OF CO
    * NABRIVA THERAPEUTICS PLC - ESTIMATES THAT IT WILL INCUR
ABOUT
$6.0 MILLION FOR SEVERANCE AND OTHER EMPLOYEE
TERMINATION-RELATED COSTS IN Q1 OF 2023
    * NABRIVA THERAPEUTICS PLC - TERMINATED ITS AGREEMENT WITH
AMPLITY
HEALTH, CONTRACT SALES ORGANIZATION RESPONSIBLE FOR PROMOTING
SIVEXTRO AND XENLETA
    * NABRIVA THERAPEUTICS PLC - EXPECTS TO TRANSITION
RESPONSIBILITY
FOR PROMOTION AND DISTRIBUTION OF SIVEXTRO BACK TO MERCK & CO.
INC.
    * NABRIVA THERAPEUTICS PLC - BOARD OF DIRECTORS CONTINUES TO
EVALUATE ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE
    * NABRIVA THERAPEUTICS -  REPAID $4.5 MILLION TO HERCULES
CAPITAL,
INCLUDING PRINCIPAL, ACCRUED & UNPAID INTEREST, FEES & OTHER
EXPENSES, UNDER LOAN DEAL

Source text for Eikon:  ID:nGNX7vtfYl 
Further company coverage:  NBRV.O 
 ((Reuters.Briefs@thomsonreuters.com;))